Takeda Pharmaceutical Co. Ltd. Wins Patent Infringement Case On ACTOS In US

Tokyo, Feb 24, 2006 (JCN) - Takeda Pharmaceutical and its US subsidiary Takeda Pharmaceuticals North America jointly announced on February 22 that they have won a patent infringement case against Mylan, Watson and Ranbaxy. The US District Court for the Southern District of New York ruled on February 21 that Takeda's patent covering the active ingredient of ACTOS (pioglitazone HCI) is valid and enforceable. Accordingly, the US Food and Drug Administration cannot approve any generic version of ACTOS until 2011, when Takeda's patent expires.

Back to news